TLDR: Fangzhou Inc. has launched its ‘XingShi’ Large Language Model (XS LLM), an advanced AI system designed to significantly enhance chronic disease management. Unveiled at the 10th H2H Healthcare Ecosystem Conference, the LLM integrates multimodal AI capabilities to improve service efficiency, personalize patient care, and optimize physician time. It powers five intelligent agents and five AI-enabled applications, aiming to provide precision interventions across the full spectrum of chronic disease management.
SHANGHAI – September 14, 2025 – Fangzhou Inc. (06086.HK), a prominent leader in AI-driven Internet healthcare solutions, today announced the release of its groundbreaking ‘XingShi’ Large Language Model (XS LLM). The unveiling took place at the company’s 10th H2H Healthcare Ecosystem Conference, marking a significant leap forward in the application of artificial intelligence for chronic disease management.
The ‘XingShi’ LLM is an advanced AI system specifically engineered to tackle critical inefficiencies prevalent in chronic disease care. Its core objectives include enhancing service efficiency, delivering highly personalized care, and optimizing the utilization of physicians’ valuable time. The model boasts robust multimodal capabilities, seamlessly integrating image and speech recognition, natural language processing, extensive medical knowledge storage, and sophisticated reasoning abilities. These features enable it to achieve advanced performance benchmarks within the medical AI domain.
Serving as the ‘core digital brain’ of Fangzhou’s platform, the XS LLM underpins a comprehensive suite of five domain-specific intelligent agents: the ‘AI Knowledge Agent,’ ‘AI Guidance Agent,’ ‘AI Pre-Consult Agent,’ ‘AI Doctor Assistant,’ and ‘AI-Electronic Medical Record (EMR) Agent.’ Together, these agents establish a closed-loop service architecture that spans the entire lifecycle of chronic disease management, from initial diagnosis to ongoing care and monitoring.
Furthermore, the model powers five distinct AI-enabled applications currently deployed across Fangzhou’s ecosystem: the AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each application is tailored to address specific clinical and patient-side use cases, facilitating real-time, precision interventions in areas such as medication guidance, patient education, diagnostic assistance, and medical reference.
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, emphasized the strategic importance of this launch, stating, “This launch is not simply a product milestone, but a strategic inflection point. XS LLM provides the technical foundation to embed AI across all layers of chronic disease management, enabling precision, scale and accessibility in healthcare delivery.”
Also Read:
- Ant Group’s AI-Powered Health App, AQ, Surpasses 140 Million Users, Expanding Healthcare Access in China
- China Unicom Accelerates AI Integration Across Industries and Households
This development is a testament to Fangzhou’s consistent build-out of its AI capabilities, evolving from its initial H2H (Hospital-to-Home) digital ecosystem and the deployment of AI-powered customer service systems to now introducing an enterprise-grade medical LLM. With China’s ‘AI+’ policy framework accelerating industrial adoption, Fangzhou anticipates that the XS LLM will serve as the cornerstone for future research and development in chronic disease management applications, reinforcing its mission to deliver scalable and precision healthcare solutions. As of June 30, 2025, Fangzhou Inc. serves 52.8 million registered users and collaborates with 229,000 physicians, solidifying its position as China’s leading online chronic disease management platform.
